THOMAS, McNERNEY & PARTNERS PROMOTES THREE MEMBERS OF ITS INVESTMENT TEAM
Kathy Tune Promoted to Principal. Christine Siu and Jason Brown, Ph.D.
Promoted to Vice President
MINNEAPOLIS, SAN FRANCISCO and STAMFORD, Conn., Jan. 8/PRNewswire/ --
Thomas, McNerney & Partners, a health care venture capital firm that
invests in life science and medical technology companies, today
announced the promotion of three members of its investment team.
Kathy Tune has been promoted to Principal. Christine Siu and Jason
Brown have been promoted to Vice President.
“We are pleased to announce the promotion of these three valuable
members of our investment staff,” said James Thomas, Partner.
“Each of these individuals has made important contributions to the firm
and these promotions recognize both their development as professionals
and the growth and maturity of the firm and its investment team.”
Kathy Tune joined the firm’s Minneapolis office in 2003 and focuses her
investment practice on the medical device sector. Kathy was
previously with Piper Jaffray and Solvay. Kathy is a board member
of Softscope Medical Technologies, Inc. Her educational background
includes an M.S. degree in Microbiology from the University of Minnesota
and an M.B.A. from the University of Minnesota’s Carlson School of
Management, where she was a Robert and Gail Buuck Scholar.
Christine Siu joined the firm’s Connecticut office in 2005 and focuses
her investment activities on venture opportunities in the public and
late-stage private markets. Prior to Thomas, McNerney, Christine
was at Warburg Pincus and Bear Stearns. Christine is a graduate of
the University of Michigan with a B.S. with distinction in Cellular
Molecular Biology and Economics and holds an M.B.A. from Harvard
Jason Brown joined Thomas, McNerney’s San Francisco office in 2007 and
focuses his investment practice in the biopharmaceutical sector.
Jason previously spent four years at Forward Ventures and conducted
research in antimicrobial drug discovery and bacterial genomics as a
postdoctoral fellow in Infectious Diseases at Johnson & Johnson
Pharmaceutical Research and Development. He is currently a board
member of Altair Therapeutics, Inc. Jason earned a Ph.D. in
Biology at the University of California, San Diego, where he was a
National Science Foundation Fellow, and a B.S. in Molecular Biology and
Biochemistry from Purdue University.
About Thomas, McNerney & Partners
Thomas, McNerney & Partners is a health care venture capital firm with
approximately $600 million under management, focused on investing in
life science and medical technology companies at all stages of
development. In addition to helping entrepreneurs launch companies
with seed and early-stage funding, the firm provides growth capital to
emerging companies to advance clinical development or for product
commercialization. Thomas, McNerney & Partners also is involved in
spinning out products and divisions from major medical device and
pharmaceutical companies, consolidating companies through roll-up
strategies and participating in structured financings for public
companies, as well as recapitalizations. The firm is targeting
investments in the pharmaceutical, medical device, biotechnology and
diagnostic sectors and in other areas utilizing medical technology
innovation. The firm has offices in Stamford, Minneapolis and San